Hemophilia Drugs Market Size, Share and Industry Analysis By Disease Indication (Hemophilia A, B & C), By Therapy Type (Recombinant Therapy, Plasma Therapy & Others), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast 2020-2029 (Includes COVID-19 Business Impact)

                                          
We have updated Hemophilia Drugs Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Hemophilia Drugs market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Hemophilia Drugs market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Hemophilia Drugs Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Hemophilia Drugs Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Hemophilia Drugs Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

  
Grifols SA
  
CSL Behring
  
Octapharma AG
  
Pfizer, Inc.
  
Bioverativ Inc.
  
FERRING L„KEMEDEL AB
  
Aptevo Therapeutics
  
Takeda Pharmaceutical Company Limited
  
Hoffmann-La Roche Ltd
  
Novo Nordisk
  
Other players

Report Coverage

With adequate and effective treatment, a patient suffering from hemophilia can live a healthy life. The missing clotting factors are injected into the patients bloodstream to cease the abnormal bleeding. With numerous innovative therapeutic options in the pipeline, the hemophilia drugs industry is expected to witness remarkable growth in near future.

The report provides qualitative and quantitative insights on the hemophilia drugs industry trends and detailed analysis of hemophilia drugs market size and growth rate for all possible segments in the market. The hemophilia drugs market is segmented by therapy type, disease indication, and distribution channel. On the basis of therapy type, the global market is segmented into recombinant therapy, plasma-derived, and others. In terms of disease indication, the market is categorized into hemophilia A, hemophilia B, and hemophilia C. Various distribution channels covered under the report are hospital pharmacy, retail pharmacy, and online pharmacy.

Geographically, the hemophilia drugs market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.

Along with this, the report analysis includes market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of coagulation factor deficiency and hemophilia, recent industry developments such as mergers & acquisitions, the regulatory scenario in key countries, new product launch, pipeline analysis, reimbursement scenario, and key industry trends.

SEGMENTATION

By Disease Indication

  
Hemophilia A
  
Hemophilia B
  
Hemophilia C

By Therapy Type

  
Recombinant Therapy
  
Plasma therapy
  
Others

By Distribution Channels

  
Hospital Pharmacy
  
Retail Pharmacy
  
Online Pharmacy

By Geography

  
North America (USA and Canada)
  
Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  
Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  
Latin America (Brazil, Mexico and Rest of Latin America)
  
Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Key Industry Developments

In October 2018, Roche received FDA approval for Hemlibra, a self -administered therapy for patients having Hemophilia A without factor VIII inhibitors.

In August 2018, Bayer announced the FDA approval for Jivi for the treatment of Hemophilia A in adolescents with age 12 years and above and adults.

In April 2018, Novo Nordisk announced the launch of Rebinyn, a coagulation factor IX for the treatment of hemophilia B in Canada.